@article{5fdafb31138c49debeb2e473e44e8666,
title = "Acute Management and Outcomes of Patients with Diabetes Mellitus Presenting to Canadian Emergency Departments with Hypoglycemia",
author = "Rowe, {Brian H.} and Mira Singh and Cristina Villa-Roel and Leiter, {Lawrence A.} and Irene Hramiak and Edmonds, {Marcia L.} and Eddy Lang and Marco Sivilotti and Frank Scheuermeyer and Andrew Worster and Jennifer Riley and Marc Afilalo and Ian Stiell and Yale, {Jean Francois} and Woo, {Vincent C.} and Samuel Campbell",
note = "Funding Information: The development of this study was made possible through the support of Merck Frosst Canada Ltd, who had no input in the manuscript or choice of journal. None of the emergency medicine authors are paid consultants of the sponsor or of CAEP. Dr. Rowe is supported by the Canadian Institutes of Health Research (CIHR) as a Tier I Canada Research Chair in Evidence-based Emergency Medicine through the Government of Canada (Ottawa, ON). Ms. Singh was supported by the Office of Research, Faculty of Medicine and Dentistry, at the University of Alberta. Dr. Villa-Roel is supported by CIHR in partnership with the Knowledge Translation Branch. Dr. Lang's research is supported by Alberta Health Services. Dr. Stiell is a Distinguished Professor and University Health Research Chair of the University of Ottawa. At the time of the study, Drs. Rowe and Sivilotti were paid senior associate editors for CAEP's scientific journal, Canadian Journal of Emergency Medicine. Dr. Rowe has received research funding from GSK and Merck, provided Continuing Medical Education (CME) on behalf of AstraZeneca and GSK, and served on an advisory board for Novartis. Dr. Lawrence Leiter has received research funding from, has provided CME on behalf of, or has acted as a consultant to AstraZeneca, BMS, BI, Eli Lilly, Merck, Novartis, Novo Nordisk, Sanofi and Servier. Dr. Vincent Woo has participated in boards, lectures and clinical trials for all of the following: Merck, Novo Nordisk, Lilly/Boehringer Ingelheim, AstraZeneca, BMS, Sanofi and Novartis. Dr. Yale has received payments for lectures and advisory boards from Sanofi, Merck, GSK, Eli Lilly, Bayer, Pfizer, Novo Nordisk, Innodia, Lifescan, Roche, Novartis, BMS, AstraZeneca, Abbott and Medtronic, and research grants from Sanofi, Pfizer, Novo Nordisk, Merck, BMS and Novartis. Dr. I. Hramiak receives research funding from AstraZeneca/Bristol Myers Squibb, Eli Lilly, Hoffmann-La Roche, GlaxoSmithKline, Janssen Ortho, Merck, Novo Nordisk, Pfizer and Sanofi-Aventis. Publisher Copyright: {\textcopyright} 2015 Canadian Diabetes Association.",
year = "2015",
month = feb,
day = "1",
doi = "10.1016/j.jcjd.2014.04.001",
language = "English",
volume = "39",
pages = "55--64",
journal = "Canadian Journal of Diabetes",
issn = "1499-2671",
publisher = "Canadian Diabetes Association",
number = "1",
}
